Zhang Luoping, Guo Helen
Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, 94720, USA.
Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, 94720, USA.
Adv Biomark Sci Technol. 2020;2:1-23. doi: 10.1016/j.abst.2020.08.001. Epub 2020 Aug 19.
Due to the unprecedented public health crisis caused by COVID-19, our first contribution to the newly launching journal, , has abruptly diverted to focus on the current pandemic. As the number of new COVID-19 cases and deaths continue to rise steadily around the world, the common goal of healthcare providers, scientists, and government officials worldwide has been to identify the best way to detect the novel coronavirus, named SARS-CoV-2, and to treat the viral infection - COVID-19. Accurate detection, timely diagnosis, effective treatment, and future prevention are the vital keys to management of COVID-19, and can help curb the viral spread. Traditionally, biomarkers play a pivotal role in the early detection of disease etiology, diagnosis, treatment and prognosis. To assist myriad ongoing investigations and innovations, we developed this current article to overview known and emerging biomarkers for SARS-CoV-2 detection, COVID-19 diagnostics, treatment and prognosis, and ongoing work to identify and develop more biomarkers for new drugs and vaccines. Moreover, biomarkers of socio-psychological stress, the high-technology quest for new virtual drug screening, and digital applications are described.
由于新型冠状病毒肺炎(COVID-19)引发了前所未有的公共卫生危机,我们对新创刊的期刊《 》的首次投稿突然转向关注当前的疫情。随着全球新型冠状病毒肺炎新增病例数和死亡人数持续稳步上升,全球医护人员、科学家和政府官员的共同目标一直是确定检测新型冠状病毒(严重急性呼吸综合征冠状病毒2,即SARS-CoV-2)的最佳方法,并治疗这种病毒感染——新型冠状病毒肺炎。准确检测、及时诊断、有效治疗和未来预防是新型冠状病毒肺炎管理的关键,有助于遏制病毒传播。传统上,生物标志物在疾病病因的早期检测、诊断、治疗和预后中起着关键作用。为了协助众多正在进行的研究和创新,我们撰写了本文,概述用于SARS-CoV-2检测、新型冠状病毒肺炎诊断、治疗和预后的已知和新出现的生物标志物,以及为识别和开发更多用于新药和疫苗的生物标志物而正在进行的工作。此外,还描述了社会心理压力的生物标志物、新型虚拟药物筛选的高科技探索以及数字应用。